// App-Quantinova.ai

e18021 : Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo.

Researchers

Presenter

  • Chukwuemeka Ikpeazu

Principal Investigators

  • Munisha Smalley

  • Baraneedharan Ulaganathan

  • Allen Thayakumar

  • Shanthappa Basavaraja

  • Hans Gertje

  • Mark Lawson

  • Aaron Goldman

Medical Centers

  • University of Miami Sylvester Comprehensive Cancer Center, Plantation, FL

  • Mitra Biotech Pvt Ltd., Woburn, MA

  • Mitra Biotech Pvt Ltd., Zion, IL

  • Mitra RxDx Inc, Woburn, MA

  • Mitra Biotech RxDx, Woburn, MA

Locations

  • United States

Companies

  • Mitra Biotech Pvt Lt

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved